Quanterix CORP 8-K filings

Quanterix will acquire Akoya Biosciences in an all-stock transaction, creating the first integrated solution for ultra-sensitive detection of bloodand tissue-based protein biomarkers.

Quanterix Corporation has completed the acquisition of Emission Inc. for an initial payment of $10 million, with potential for additional payments based on performance and technical milestones.

Quanterix Corporation has announced its acquisition of EMISSION Inc. for $10 million upfront, with potential for an additional $60 million based on milestones, to vertically integrate proprietary bead technology.

Quanterix Corporation received a notification from Nasdaq for not filing its quarterly report on time due to an ongoing financial restatement.

Quanterix reported preliminary third-quarter results showing double-digit revenue growth but also announced a restatement of prior financial statements due to accounting errors.

Quanterix Corporation filed an amendment to its original 8-K report to include the appointment of Jeffrey T. Elliott to the Nominating and Governance Committee of the Board.

Quanterix Corporation has appointed Ivana Magovevi-Liebisch, Ph.D., J.D., a seasoned biopharmaceutical executive, to its Board of Directors, effective immediately.

Quanterix Corporation has appointed Jeffrey Elliott, a seasoned executive with extensive experience in the medical diagnostics industry, to its Board of Directors, effective immediately.

Quanterix announced its second quarter 2024 financial results, highlighting a 10.8% increase in revenue year-over-year and progress in Alzheimer's disease diagnostics.

Quanterix Corporation held its 2024 annual meeting, electing two new directors, approving executive compensation, and ratifying its independent auditor.

Quanterix Corporation has appointed Michael Miller as its new Chief Operating Officer, succeeding Daniel Pikora, who resigned on May 21, 2024.

Quanterix announced a 12.7% increase in revenue for the first quarter of 2024, along with FDA Breakthrough Device designation for its Simoa P-tau217 blood test.

Quanterix Corporation has amended employment agreements for its CEO and CFO, increasing severance benefits, and announced that director Laurie Olson will not seek re-election at the upcoming annual meeting.

Quanterix announced its fourth quarter and full year 2023 financial results, highlighting a successful corporate transformation and revenue growth.

Quanterix has rescheduled its Q4 and full year 2023 earnings call to February 29, 2024, to align with its 10-K filing, and reaffirms its 2023 financial guidance.

Quanterix Corporation's Compensation Committee approved the 2024 annual cash incentive plan and amended employment agreements for its CEO and CFO, including salary continuation provisions upon certain terminations.

Quanterix Corporation shared preliminary unaudited financial results for 2023, projecting a high 50s GAAP gross margin and approximately 50% non-GAAP gross margin.